中金发表研究报告指，阿里健康(00241.HK) 全年收入305.98亿人民币，按年升13.2%；归母净利润14.32亿人民币，按年升62.1%；non-GAAP净利润19.5亿人民币，按年升35.6%，基本符合市场预期。
公司核心主业维持稳健发展，利润端表现稳中有进，盈利产出或为当前经营侧重点。考虑到公司当前战略重心或相对倾斜利润端产出，中金上调阿里健康2026年度表观归母净利润8.2%至19.34亿人民币，首次引入2027年度归母净利润21.78亿人民币。上调公司目标价17%至5.5港元，维持“跑赢行业”评级。(ad/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-21 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.